On September 23, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the Benzinga Healthcare Small Cap Conference on Wednesday, September 29, 2021 (Press release, Scopus BioPharma, SEP 23, 2021, View Source [SID1234590205]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will present on the launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology. Scopus announced the launch of Duet on September 2, 2021.
Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting on behalf of the company. Dr. Horsager’s presentation will be part of the Green Track on Wednesday, September 29, 2021. The presentation will be streamed live beginning at 4:20 PM EST and will be accessible by clicking here.
If you are an institutional investor interested in scheduling a one-on-one meeting with the company, please click here to register for the conference and request a one-on-one meeting.
About the Duet Platform
Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.
The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:
• RNA silencing CpG-STAT3siRNA ("DUET-01")
• Antisense CpG-STAT3ASO ("DUET-02")
• DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")
DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.